Prev Arrow Stocks

IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Down 1.7% Today

Morpher AI identified a bearish signal. The stock price may continue to fall based on the momentum of the negative news.

What is IDEXX Laboratories Inc.?

IDEXX Laboratories (IDXX) is a company specializing in veterinary diagnostics and software, offering products and services for the animal healthcare industry.

Why is IDEXX Laboratories Inc. going down?

IDXX stock is down 1.7% on Feb 2, 2026 16:40

  • Despite posting impressive Q4 earnings and revenue exceeding predictions, IDXX saw a downward trend in the market.
  • A slight decline in stock price before the market opened may stem from heightened investor expectations, as the company emphasized robust pet health services and efficient cost control.
  • Investors' varied responses could be linked to a marginal miss in earnings per share ($0.01) alongside revenue surpassing forecasts, leading to cautiousness among traders.
  • IDXX's shares declining by 0.9% year-to-date, in contrast to the broader market's 1.4% gain (S&P 500), could have influenced the market downturn, with investors potentially anticipating more substantial growth despite the company's strong financial performance.

IDXX Price Chart

IDXX Technical Analysis

IDXX News

IDEXX Laboratories Surpasses Q4 Earnings and Revenue Expectations

IDEXX Laboratories reported strong Q4 and full-year 2025 results, beating EPS and revenue estimates, driven by growth in its Companion Animal Group diagnostics. Despite strong financial performance and positive 2026 guidance, the stock saw a slight premarket dip, potentially reflecting high investor expectations. The company highlights continued strength in pet health services and effective cost management.

https://mlq.ai/news/idexx-laboratories-surpasses-q4-earnings-and-revenue-expectations/

0 News Article Image IDEXX Laboratories Surpasses Q4 Earnings and Revenue Expectations

Idexx: Q4 Earnings Snapshot

Idexx Laboratories Inc. reported strong fourth-quarter results, surpassing Wall Street expectations. The company announced net income of $248.2 million, or $3.08 per share, on revenue of $1.09 billion. For the full year, Idexx posted significant profit and revenue, and provided optimistic guidance for the upcoming year's earnings and revenue.

https://www.bitget.com/amp/news/detail/12560605179025

1 Missing News Article Image Idexx: Q4 Earnings Snapshot

Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

Idexx Laboratories (IDXX) reported Q4 earnings of $3.08 per share, surpassing the Zacks Consensus Estimate of $2.93 and exceeding year-ago earnings of $2.62. Revenue for the quarter reached $1.09 billion, beating the consensus by 1.86% and improving on the previous year's $954.29 million. Despite these strong results, Idexx shares have seen a slight decline of 0.9% year-to-date, contrasting with the S&P 500's gain of 1.4%.

https://finance.yahoo.com/news/idexx-laboratories-idxx-beats-q4-124001104.html

2 News Article Image Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

IDEXX Laboratories (IDXX) Q4 FY25 sales rise in double digits

IDEXX Laboratories (IDXX) reported a strong double-digit revenue growth in the fourth quarter of fiscal 2025, reaching $1.09 billion, a 14% increase year-over-year. Companion Animal Group and Water segments were key drivers of this growth, with earnings per share up 18%. The company provided an optimistic outlook for fiscal 2026, forecasting continued revenue and EPS growth.

https://news.alphastreet.com/idexx-laboratories-idxx-q4-fy25-sales-rise-in-double-digits/amp/

3 News Article Image IDEXX Laboratories (IDXX) Q4 FY25 sales rise in double digits

IDEXX Labs earnings missed by $0.01, revenue topped estimates

IDEXX Labs (NASDAQ: IDXX) reported fourth-quarter EPS of $2.92, narrowly missing analyst estimates by $0.01, while its revenue of $1.09 billion surpassed the consensus estimate of $1.07 billion. The company provided fiscal year 2026 guidance, projecting EPS between $14.29 and $14.80 and revenue between $4.63 billion and $4.72 billion. Shares of IDEXX Labs have shown significant growth over the past year, increasing by 42.94%.

https://www.investing.com/news/earnings/idexx-labs-earnings-missed-by-001-revenue-topped-estimates-4478311

4 Missing News Article Image IDEXX Labs earnings missed by $0.01, revenue topped estimates

IDEXX Laboratories Inc. Price History

21.07.2024 - IDXX Stock was down 0.6%

  • The downward trend in IDXX today may be due to the following reasons:
  • Profit-taking: Investors who have realized substantial profits from holding IDXX stock for an extended period may have opted to sell shares to secure their gains, resulting in a decrease in the stock price.
  • Market correction: Following a period of sustained success, IDXX might be undergoing a natural market correction as investors review their positions and explore new investment prospects.
  • External influences: Economic conditions or industry-related developments could also be impacting the bearish movement in IDXX today, prompting investors to modify their investment portfolios accordingly.

30.00.2025 - IDXX Stock was up 5.2%

  • IDXX's upturn today is linked to market expectations of robust Q4 earnings, attributed to the company's successful execution of strategic initiatives.
  • Investors are positive about IDXX's outlook, anticipating growth and profitability in the upcoming period.
  • The favorable outlook for IDXX mirrors the market's confidence in the company's capability to deliver value and sustain a competitive position in the veterinary diagnostics sector.

03.10.2025 - IDXX Stock was up 1.5%

  • Expectations are high for IDEXX Laboratories' upcoming release of Q3 earnings, with analysts predicting an increase in quarterly earnings compared to the previous year. This optimistic forecast likely played a role in the recent bullish movement in the stock.
  • Over the past decade, IDXX has demonstrated impressive long-term performance, consistently outperforming the market and delivering substantial returns for investors. This consistent track record could be attracting more interest from investors.
  • A Hershey analyst's shift in sentiment towards IDEXX Laboratories, no longer holding a bearish view, combined with other top analyst upgrades, may be bolstering investor confidence in the company's future prospects and contributing to the current bullish trend in the stock.

03.10.2025 - IDXX Stock was up 0.1%

  • IDXX stock witnessed a notable upturn today after announcing impressive Q3 earnings that surpassed expectations, along with an optimistic future forecast.
  • The company disclosed adjusted earnings of $3.22 per share, marking a 15% year-over-year increase and exceeding analyst estimates.
  • Analysts had predicted earnings of $3.14 per share, underscoring confidence in the company's ability to deliver robust financial results.
  • Top Wall Street analysts have upgraded their outlook on IDXX, reflecting an increasing bullish sentiment among investors.

31.09.2024 - IDXX Stock was down 9.5%

  • Third-quarter earnings of IDXX surpassed adjusted EPS predictions but fell short of revenue consensus, hinting at possible hurdles in revenue expansion.
  • The deceleration in revenue growth is possibly linked to a decline in veterinary visits, influencing the company's sales trajectory.
  • Noteworthy growth in segments such as CAG and Water was eclipsed by the lower-than-expected revenue, possibly instigating a downward trend in the stock's value.
  • Concerns among investors about IDXX's future growth sustainability are palpable, with guidance adjustments contributing to the stock's market decline.

01.04.2025 - IDXX Stock was up 9.0%

  • IDEXX Laboratories has showcased an average annual return of 21.28% over the past 10 years.
  • The company boasts a market capitalization of $35.41 billion, indicating its market strength and resilience.
  • Today, IDXX experienced a bullish movement likely attributed to its consistent growth and robust financial performance that has attracted investors seeking high returns.

01.04.2025 - IDXX Stock was up 9.0%

  • Strong Q1 earnings were reported by IDXX, surpassing expectations and resulting in an increased outlook for the fiscal year 2025. This positive financial performance has led to heightened investor interest and a rise in the stock price.
  • Over the past decade, IDXX has consistently outperformed the market, achieving an impressive annualized return of 21.28%. This track record has likely fostered investor confidence in the company's future growth prospects.
  • The notable financial results and a history of market-beating returns have fueled a positive trend in IDXX stock, reflecting optimistic investor attitudes and confidence in the company's future prospects.

04.07.2025 - IDXX Stock was up 4.2%

  • IDEXX reported strong Q2 earnings, surpassing expectations with earnings of $3.50 per share and revenue reaching $1.11 billion.
  • The impressive 11% growth in Companion Animal Group sales contributed to the revenue increase, showcasing the company's strong performance in its core business segment.
  • The raised full-year EPS guidance and revenue forecast indicate a positive outlook for IDEXX, reassuring investors and justifying the premium valuation of the stock.
  • Overall, the market responded positively to IDEXX's robust financial results and optimistic future prospects, driving the stock price higher.

21.10.2025 - IDXX Stock was up 5.0%

  • IDXX stock experienced a strong bullish movement today, breaking out above the 20-day moving average, indicating positive momentum.
  • The news about Molina (MOH) securing a deal to serve Florida's Medicaid members is unrelated to IDXX's bullish movement.
  • Investors may have reacted positively to the breakout above the moving average, signaling potential upside for IDXX in the near term.
  • The breakout could be a result of increased investor confidence in the company's growth prospects and continued demand for its veterinary diagnostic solutions.

02.01.2026 - IDXX Stock was down 1.7%

  • Despite posting impressive Q4 earnings and revenue exceeding predictions, IDXX saw a downward trend in the market.
  • A slight decline in stock price before the market opened may stem from heightened investor expectations, as the company emphasized robust pet health services and efficient cost control.
  • Investors' varied responses could be linked to a marginal miss in earnings per share ($0.01) alongside revenue surpassing forecasts, leading to cautiousness among traders.
  • IDXX's shares declining by 0.9% year-to-date, in contrast to the broader market's 1.4% gain (S&P 500), could have influenced the market downturn, with investors potentially anticipating more substantial growth despite the company's strong financial performance.

31.06.2025 - IDXX Stock was down 5.1%

  • Despite high expectations for Q2 earnings with anticipated growth in various segments, IDXX experienced a strong bearish movement today.
  • The market may have reacted negatively to the actual earnings release, which potentially fell short of the optimistic forecasts.
  • Investors might have been disappointed by certain aspects of the earnings report, such as lower-than-expected revenue or guidance for future performance.
  • It's possible that profit-taking or market dynamics unrelated to the company's fundamentals also contributed to the bearish movement in IDXX's stock price today.

05.07.2025 - IDXX Stock was down 5.6%

  • IDEXX Laboratories (IDXX) stock experienced a bearish movement despite surpassing earnings expectations and posting strong Q2 results.
  • The market may have reacted negatively due to profit-taking by investors after a period of growth following the positive earnings report.
  • Despite the positive news of revenue growth, EPS beat, and raised guidance, the stock might have been impacted by broader market trends or sector rotation.
  • Investors might be cautious about the stock's valuation or potential future challenges despite the company's strong performance.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.